Management of Patients with Systemic Lupus Erythematosus at the Stage of Primary Care: Answers to Frequently Asked Questions

##plugins.themes.bootstrap3.article.main##

І. Ю. Головач
Є. Д. Єгудіна

Abstract

Systemic lupus erythematosus (SLE) is an autoimmune disease in which many systems and organs are affected, including skin, musculoskeletal system, renal, lungs, hematologic,  cardiovascular, nervous and reproductive systems. Family physicians should be familiar with the manifestations of lupus to aid in early diagnosis, monitoring patients with mild disease, recognizing warning signs of exacerbation that require referral to a rheumatologist, and helping to monitor disease activity and treatment in patients with moderate to severe disease. The American College of Rheumatology offers 11 classification criteria for SLE diagnosis. If a patient meets at least four criteria, lupus can be diagnosed with 95% specificity and 85% sensitivity. All patients with SLE should receive information about the disease, regular counseling, and medical support. Hydroxychloroquine is the cornerstone of treatment, reducing the frequency of disease flares and other common symptoms. Low doses of glucocorticoids can be used to treat most manifestations of SLE. The use of immunosuppressants and cytotoxic agents depends on depends on the body systems affected. To optimize treatment, to improve chronic care, prevent and screen for the comorbidity presence, strong collaboration between a rheumatologist, a patient, and a family physician is important. In this review, we summarize practical recommendations for family physiacians and provide updated information regarding the early diagnosis and management of a patient with SLE, discuss the main associated diseases that complicate the course of the disease, and recommended preventive measures.

##plugins.themes.bootstrap3.article.details##

How to Cite
Головач, І. Ю., & Єгудіна, Є. Д. (2019). Management of Patients with Systemic Lupus Erythematosus at the Stage of Primary Care: Answers to Frequently Asked Questions. Family Medicine, (2), 31–42. https://doi.org/10.30841/2307-5112.2.2019.174634
Section
For practicing physicians

References

Aljohani R, Gladman DD, Su J, Urowitz MB. Comparison of systemic lupus erythematosus (SLE) patients managed early after diagnosis in specialty versus community care clinics. Clin Rheumatol. 2017;36:1773–8. doi: 10.1007/s10067-017-3713-7.

Almaani S, Meara A, Rovin BH. Update on lupus nephritis. Clin J Am Soc Nephrol. 2017; 12:825–35. doi: 10.2215/CJN.0578061

Andreoli L, Bertsias GK, Agmon-Levin N, Brown S, Cervera R, Costedoat-Chalumeau N, et al. EULAR recommendations for women’s health and the management of family planning, assisted reproduction, pregnancy and menopause in patients with systemic lupus erythematosus and/or antiphospholipid syndrome. Ann Rheum Dis. 2017;76:476–85. doi: 10.1136/annrheumdis-2016-209770

American College of Rheumatology Ad Hoc Committee on Systemic Lupus Erythematosus Guidelines. Guidelines for referral and management of systemic lupus erythematosus in adults. Arthritis Rheum. 1999; 42(9): 1785-1796.

Azrielant S, Tiosano S, Watad A, Mahroum N, Whitby A, Comaneshter D, et al. Correlation between systemic lupus erythematosus and malignancies: a cross-sectional populationbased study. Immunol Res. 2017; 65:464–9. doi: 10.1007/s12026-016-8885-8

Bertsias GK, Pamfil C, Fanouriakis A, Boumpas DT. Diagnostic criteria for systemic lupus erythematosus: has the time come? Nat Rev Rheumatol.2013;9:687–94. doi: 10.1038/nrrheum.2013.103

Bragazzi NL, Watad A, Sharif K, Adawi M, Aljadeff G, Amital H, et al. Advances in our understanding of immunization and vaccines for patients with systemic lupus erythematosus. Expert Rev Clin Immunol.2017;13:939–49. doi: 10.1080/1744666X.2017.1361321

Burgos PI, Alarcón GS. Preventive health services for systemic lupus erythematosus patients: whose job is it? Arthritis Res Ther. 2010;12(3):124.

Calixto OJ, Franco JS, Anaya JM. Lupus mimickers. Autoimmu Rev. 2014;13:865–72. doi: 10.1016/j.autrev.2014.05.002

Carmier D, Marchand-Adam S, Diot P, Diot E. Respiratory involvement in systemic lupus erythematosus. Rev Mal Respir. 2010;27(8):e66-e78.

Cattalini M, Soliani M, Caparello MC, Cimaz R. Sex differences in pediatric rheumatology. Clin Rev Allergy Immunol. 2017. doi: 10.1007/s12016-017-8642-3. [Epub ahead of print]

Cavazzana I, Andreoli L, Limper M, Franceschini F, Tincani A. Update on antiphospholipid syndrome: ten topics in 2017. Curr Rheumatol Rep. 2018;20:15. doi: 10.1007/s11926-018-0718-4

Centers for Disease Control and Prevention (CDC). Use of 13-valent pneumococcal conjugate vaccine and 23-valent pneumococcal polysaccharide vaccine for adults with immunocompromising conditions: recommendations of the Advisory Committee on Immunization Practices (ACIP). MMWR Morb Mortal Wkly Rep. 2012;61(40):816-819.

Cervera R, Piette JC, Font J, Khamashta MA, Shoenfeld Y, Camps MT, et al. Antiphospholipid syndrome: clinical and immunologic manifestations and patterns of disease expression in a cohort of 1,000 patients. Arthritis Rheum. 2002;46:1019–27. doi: 10.1002/art.10187

Chang CC, Chang YS, Chen WS, Chen YH, Chen JH. Effects of annual influenza vaccination on morbidity and mortality in patients with Systemic Lupus Erythematosus: a Nationwide Cohort Study. Sci Rep. 2016;6:37817. doi:10.1038/srep37817

Cojocaru M, Cojocaru IM, Silosi I, Vrabie CD. Manifestations of systemic lupus erythematosus. Maedica (Buchar). 2011;6(4):330-336.

Culwell KR, Curtis KM, del Carmen Cravioto M. Safety of contraceptive method use among women with systemic lupus erythematosus: a systematic review. Obstet Gynecol. 2009;114(2 pt 1):341-353.

Drakoulogkona O, Barbulescu AL, Rica I, Musetescu AE, Ciurea PL. The outcome of patients with lupus nephritis and the impact of cardiovascular risk factors. Curr Health Sci J. 2011;37(2):70-74.

Farinha F, Freitas F, Agueda A, Cunha I, Barcelos A. Concerns of patients with systemic lupus erythematosus and adherence to therapy – a qualitative study. Patient Prefer Adher. 2017;11:1213–9. doi: 10.2147/PPA.S137544

Ferucci ED, Johnston JM, Gordon C, Helmick CG, Lim SS. Prevalence of mixed connective tissue disease in a population-based registry of American Indian/Alaska Native People in 2007. Arthritis Care Res. 2017;69:1271–5. doi: 10.1002/acr.23135

Gergianaki I, Fanouriakis A, Repa A, TzanakakisM, Adamichou C, Pompieri A, et al. Epidemiology and burden of systemic lupus erythematosus in a Southern European population: data from the community-based lupus registry of Crete, Greece. Ann Rheum Dis. 2017;76:1992–2000.doi: 10.1136/annrheumdis-2017-211206

Golder V, Ooi JJY, Antony AS, Ko T, Morton S, Kandane-Rathnayake R, et al. Discordance of patient and physician health status concerns in systemic lupus erythematosus. Lupus. 2018;27:501–6. doi: 10.1177/0961203317722412

Gonzalez LA, Alarcon GS. The evolving concept of SLE comorbidities. Expert Rev Clin Immunol. 2017;13:753–68. doi: 10.1080/1744666X.2017.1327353

Goobie GC, Bernatsky S, Ramsey-Goldman R, Clarke AE. Malignancies in systemic lupus erythematosus: a 2015 update. Curr Opin Rheumatol. 2015;27:454–60. doi: 10.1097/BOR.0000000000000202

Gordon C, Amissah-Arthur MB, Gayed M, Brown S, Bruce IN, D’Cruz D, et al. The British Society for Rheumatology guideline for the management of systemic lupus erythematosus in adults. Rheumatology. 2018;57:e1–45. doi: 10.1093/rheumatology/kex286

Grein IH, Groot N, Lacerda MI, Wulffraat N, Pileggi G. HPV infection and vaccination in Systemic Lupus Erythematosus patients: what we really should know. Pediatr Rheumatol Online J. 2016;14:12. doi: 10.1186/s12969-016-0072-x

Jakes RW, Bae SC, Louthrenoo W, Mok CC, Navarra SV, Kwon N. Systematic review of the epidemiology of systemic lupus erythematosus in the Asia-Pacific region: prevalence, incidence, clinical features, and mortality. Arthritis Care Res (Hoboken). 2012;64(2):159-168.

Hahn BH, McMahon MA, Wilkinson A, et al. American College of Rheumatology guidelines for screening, treatment, and management of lupus nephritis. Arthritis Care Res (Hoboken). 2012; 64(6): 797–808. doi: 10.1002/acr.21664

Hale ED, Treharne GJ, Lyons AC, et al. “Joining the dots” for patients with systemic lupus erythematosus: personal perspectives of health care from a qualitative study. Ann Rheum Dis. 2006;65(5):585-589.

Haliloglu S, Carlioglu A, Akdeniz D, Karaaslan Y, Kosar A. Fibromyalgia in patients with other rheumatic diseases: prevalence and relationship with disease activity. Rheumatol Int. 2014;34:1275–80. doi: 10.1007/s00296-014-2972-8

Hedrich CM. Epigenetics in SLE. Curr Rheumatol Rep. 2017;19:58. doi: 10.1007/s11926-017-0685-1

Heinlen LD, McClain MT, Merrill J, Akbarali YW, Edgerton CC, Harley JB, et al. Clinical criteria for systemic lupus erythematosus precede diagnosis, and associated autoantibodies are present before clinical symptoms. Arthritis Rheum. 2007;56:2344–51. doi: 10.1002/art.22665

Hsiao YP, Tsai JD, Muo CH, Tsai CH, Sung FC, Liao YT, et al. Atopic diseases and systemic lupus erythematosus: an epidemiological study of the risks and correlations. Int J Environ Res Public Health. 2014;11:8112–22. doi: 10.3390/ijerph110808112

Iaccarino L, Gatto M, Bettio S, Caso F, Rampudda M, Zen M, et al. Overlap connective tissue disease syndromes. Autoimmu Rev. 2013;12:363–73.doi: 10.1016/j.autrev.2012.06.004

Ines L, Silva C, Galindo M, Lopez-Longo FJ, Terroso G, Romao VC, et al. Classification of systemic lupus erythematosus: systemic lupus international collaborating clinics versus American College of rheumatology criteria. A comparative study of 2,055 patients from a real-life, International systemic lupus erythematosus cohort. Arthritis Care Res. 2015; 67:1180–5. doi: 10.1002/acr.22539

Izmirly PM, Wan I, Sahl S, Buyon JP, Belmont HM, Salmon JE, et al. The incidence and prevalence of systemic lupus erythematosus in New York County (Manhattan), New York: the manhattan lupus surveillance program. Arthritis Rheum.2017;69:2006–17. doi: 10.1002/art.40192

Kamphuis S, Silverman ED. Prevalence and burden of pediatric-onset systemic lupus erythematosus. Nat Rev Rheumatol. 2010; 6:538–46. doi: 10.1038/nrrheum.2010.121

Katz P, Gregorich S, Yazdany J, Trupin L, Julian L, Yelin E, et al. Obesity and its measurement in a community-based sample of women with systemic lupus erythematosus. Arthritis Care Res. 2011;63:261–8. doi: 10.1002/acr.20343

Keane MP, Lynch JP III. Pleuropulmonary manifestations of systemic lupus erythematosus. Thorax. 2000;55(2):159-166.

Lam NC, Ghetu MV, Bieniek ML. Systemic lupus erythematosus: primary care approach to diagnosis and management. Am Family Physician. 2016;94:284–94.

Lateef A, Petri M. Systemic lupus erythematosus and pregnancy. Rheum Dis Clin North Am. (2017) 43:215–26. doi: 10.1016/j.rdc.2016.12.009

Leuchten N, Hoyer A, Brinks R, Schoels M, Schneider M, Smolen J, et al. Performance of antinuclear antibodies for classifying systemic lupus erythematosus: a systematic literature review and meta-regression of diagnostic data. Arthritis Care Res. 2018;70:428–38. doi: 10.1002/acr.23292

Lewis MJ, Jawad AS. The effect of ethnicity and genetic ancestry on the epidemiology, clinical features and outcome of systemic lupus erythematosus. Rheumatology. 2017; 56(suppl. 1):i67–77. doi: 10.1093/rheumatology/kew399

Longo DL, Fauci AS, Kasper DL, Hauser SL, Jameson JL, Loscalzo J, eds. Harrison’s Principles of Internal Medicine. 18th ed. New York, NY: McGraw-Hill; 2012.

Madhok R, Wu O. Systemic lupus erythematosus. BMJ Clin Evid. 2009; 2009:1123.

Muangchan C, van Vollenhoven RF, Bernatsky SR, et al. Treatment algorithms in systemic lupus erythematosus. Arthritis Care Res (Hoboken). 2015; 67(9):1237-1245.

Murray SG, Schmajuk G, Trupin L, Gensler L, Katz PP, Yelin EH, et al. National lupus hospitalization trends reveal rising rates of herpes zoster and declines in pneumocystis pneumonia. PLoS ONE. 2016;11:e0144918. doi: 10.1371/journal.pone.0144918

Muscal E, Brey RL. Neurologic manifestations of systemic lupus erythematosus in children and adults. Neurol Clin. 2010;28(1):61-73.

Narain S, Richards HB, Satoh M, et al. Diagnostic accuracy for lupus and other systemic autoimmune diseases in the community setting. Arch Intern Med. 2004;164(22):2435-2441.

Nightingale AL, Davidson JE, Molta CT, Kan HJ, McHugh NJ. Presentation of SLE in UK primary care using the Clinical Practice Research Datalink. Lupus Sci Med.2017; 4:e000172. doi: 10.1136/lupus-2016-000172

Parks CG, de Souza Espindola Santos A, Barbhaiya M, Costenbader KH. Understanding the role of environmental factors in the development of systemic lupus erythematosus. Best Pract Res Clin Rheumatol. 2017;31:306–20. doi: 10.1016/j.berh.2017.09.005

Petri M, Orbai AM, Alarcón GS, et al. Derivation and validation of the Systemic Lupus International Collaborating Clinics classification criteria for systemic lupus erythematosus. Arthritis Rheum. 2012;64(8):2677-2686.

Pons-Estel GJ, Ugarte-Gil MF, Alarcon GS. Epidemiology of systemic lupus erythematosus. Expert Rev Clin immunology. 2017;13:799–814. doi: 10.1080/1744666X.2017.1327352

Pramanik B. Diagnosis of systemic lupus erythematosus in an unusual presentation: what a primary care physician should know. Curr Rheumatol Rev. 2014;10:81–6. doi: 10.2174/1573397111999150128103237

Rees F, Doherty M, Grainge M, Davenport G, Lanyon P, Zhang W. The incidence and prevalence of systemic lupus erythematosus in the UK, 1999-2012. Ann Rheum Dis. 2016; 75:136–41. doi: 10.1136/annrheumdis-2014-206334

Rees F, Doherty M, Grainge MJ, Lanyon P, Zhang W. The worldwide incidence and prevalence of systemic lupus erythematosus: a systematic review of epidemiological studies. Rheumatology.2017;56:1945–61. doi: 10.1093/rheumatology/kex260

Rees F, Doherty M, Lanyon P, Davenport G, Riley RD, Zhang W, et al. Early clinical features in systemic lupus erythematosus: can they be used to achieve earlier diagnosis? A risk prediction model. Arthritis Care Res. 2017;69:833–41. doi: 10.1002/acr.23021

Ruiz-Irastorza G, Ramos-Casals M, Brito-Zeron P, Khamashta MA. Clinical efficacy and side effects of antimalarials in systemic lupus erythematosus: a systematic review. Ann Rheum Dis. 2010;69(1):20-28.

Schmajuk G, Hoyer BF, Aringer M, Johnson SR, Daikh DI, Dorner T, et al. Multi-center delphi exercise reveals important key items for classifying systemic lupus erythematosus. Arthritis Care Res. 2017. doi: 10.1002/acr.23503. [Epub ahead of print].

Schoenfeld SR, Kasturi S, Costenbader KH. The epidemiology of atherosclerotic cardiovascular disease among patients with SLE: a systematic review. Semin Arthritis Rheum. 2013;43:77–95. doi: 10.1016/j.semarthrit.2012.12.002

Shen TC, Lin CL, Chen CH, Tu CY, Hsia TC, Shih CM, et al. Increased risk of chronic obstructive pulmonary disease in patients with systemic lupus erythematosus: a population-based cohort study. PLoS ONE. 2014;9:e91821.doi: 10.1371/journal.pone.0091821

Sinicato NA, da Silva Cardoso PA, Appenzeller S. Risk factors in cardiovascular disease in systemic lupus erythematosus. Curr Cardiol Rev. 2013;9(1):15-19.

Sivaraj RR, Durrani OM, Denniston AK, Murray PI, Gordon C. Ocular manifestations of systemic lupus erythematosus. Rheumatology (Oxford). 2007;46(12):1757-1762.

Tedeschi SK, Johnson SR, Boumpas D, Daikh D, Dorner T, Jayne D, et al. Developing and refining new candidate criteria for systemic lupus erythematosus classification: an international collaboration. Arthritis Care Res. 2018;70:571–81. doi: 10.1002/acr.23317

Teruel M, Alarcon-Riquelme ME. The genetic basis of systemic lupus erythematosus: what are the risk factors and what have we learned. J Autoimmu.2016;74:161–75. doi: 10.1016/j.jaut.2016.08.001

Tselios K, Koumaras C, Gladman DD, UrowitzMB. Dyslipidemia in systemic lupus erythematosus: just another comorbidity? Semin Arthritis Rheum. 2016;45:604–10. doi: 10.1016/j.semarthrit.2015.10.010

Ugarte-Gil MF, Pons-Estel GJ, Molineros J, Wojdyla D, McGwin G, Jr., Nath SK, et al. Disease features and outcomes in United States lupus patients of Hispanic origin and their Mestizo counterparts in Latin America: a commentary. Rheumatology. 2016; 55:436–40. doi: 10.1093/rheumatology/kev280

Urowitz MB, Kagal A, Rahman P, Gladman DD. Role of specialty care in the management of patients with systemic lupus erythematosus. J Rheumatol. 2002; 29:1207–10.

Watad A, Tiosano S, Bragazzi NL, Brigo F, Comaneshter D, Cohen AD, et al. Epilepsy among Systemic Lupus Erythematosus Patients: insights from a Large Database Analysis. Neuroepidemiology. 2018;50:1–6. doi: 10.1159/000485136

Wei S, Lai K, Yang Z, Zeng K. Systemic lupus erythematosus and risk of preterm birth: a systematic review and meta-analysis of оbservational studies. Lupus. 2017; 26:563-71. doi: 10.1177/0961203316 686704

Yang Y, Thumboo J, Earnest A, Yong SL, Fong KY. The effect of comorbidity on hospital mortality in patients with SLE from an Asian tertiary hospital. Lupus. 2014; 23:714–20. doi: 10.1177/0961203314522340

Zhang L, Fu T, Yin R, Zhang Q, Shen B. Prevalence of depression and anxiety in systemic lupus erythematosus: a systematic review and meta-analysis. BMC Psychiatry. 2017; 17:70. doi: 10.1186/s12888-017-1234-1

Zoma A. Musculoskeletal involvement on systemic lupus erythematosus. Lupus. 2004;13(11):851-853.

Zuily S, Regnault V, Selton-Suty C, et al. Increased risk for heart valve disease associated with antiphospholipid antibodies in patients with systemic lupus erythematosus: meta-analysis of echocardiographic studies. Circulation. 2011;124(2):215-224.